Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Synaptogenix, Inc. (SNPX : NSDQ)
 
 • Company Description   
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.83 Daily Weekly Monthly
20 Day Moving Average: 60,660 shares
Shares Outstanding: 6.81 (millions)
Market Capitalization: $32.89 (millions)
Beta:
52 Week High: $14.50
52 Week Low: $3.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.49% -22.74%
12 Week -25.81% -19.50%
Year To Date -43.24% -32.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1185 Avenue of the Americas 3rd Floor
-
New York,NY 10036
USA
ph: 973-242-0005
fax: -
brett@haydenir.com http://www.synaptogen.com
 
 • General Corporate Information   
Officers
Alan J. Tuchman - Chief Executive Officer
Joshua N. Silverman - Chairman
William S. Singer - Vice-Chairman
Robert Weinstein - Chief Financial Officer
Bruce T. Bernstein - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87167T201
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 6.81
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $32.89 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.04
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -39.56
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -38.24
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 48.33
12/31/21 - 17.80
09/30/21 - 32.12
Quick Ratio
03/31/22 - -
12/31/21 - 17.80
09/30/21 - 32.12
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.65
12/31/21 - 5.02
09/30/21 - 5.11
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©